{
    "clinical_study": {
        "@rank": "139746", 
        "acronym": "DGF", 
        "arm_group": [
            {
                "arm_group_label": "Active", 
                "arm_group_type": "Experimental", 
                "description": "Eculizumab will be administered by intravenous (IV) infusion over 25-45 minutes for two doses (on day of transplant then 18-24 hours later)."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be administered by intravenous (IV) infusion over 25-45 minutes for two doses (on day of transplant then 18-24 hours later)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if Eculizumab is safe and could be used to prevent\n      delayed graft function following kidney transplantation."
        }, 
        "brief_title": "A Trial for the Prevention of DGF After Kidney Transplantation", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Delayed Graft Function", 
        "condition_browse": {
            "mesh_term": "Delayed Graft Function"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject male or female, 18 years or older\n\n          -  Subject with dialysis dependent renal failure (initiated more than 2      months\n             prior to transplant)\n\n          -  Subject is to receive a first kidney transplant from a SCD or ECD deceased donor with\n             a DGF risk score using the Irish scale of  \u2265 25% (to be determined prior to surgery\n             and before randomization)\n\n          -  Subject able to provide written informed consent\n\n          -  Subject must be willing and able to comply with the requirements of the study\n             protocol\n\n          -  Female subjects of child-bearing potential must have a negative serum pregnancy test\n             (serum beta-hCG) and must be practicing an effective, reliable, and medically\n             approved contraceptive regimen at the time of consent and for up to 5 months\n             following discontinuation of treatment\n\n        Exclusion Criteria:\n\n          -  Subject to receive a multi-organ transplant\n\n          -  Subject to receive kidney(s) from donors < 6 years of age\n\n          -  Subject to receive a dual kidney transplant (from same donor, including en bloc)\n\n          -  Subject to receive a living donor kidney\n\n          -  Subject is highly sensitized to the donor (as determined by local center\n             practice-examples of such testing may be but not required or limited to T or B flow\n             cytometry, or lymphocytotoxicity).\n\n          -  Subject has received a previous transplant\n\n          -  Subject is participating in another investigational study\n\n          -  Subject has a body mass index (BMI) >40 kg/m2 at screening\n\n          -  Subject will be the recipient of an A, B, O Blood Glycoproteins (ABO)(blood type)\n             incompatible kidney (A2 donors to B and O recipients will be allowed if the site has\n             the ability to confirm A2 subtype)\n\n          -  Subject will receive a kidney from a donation after cardiac death (DCD) donor\n\n          -  Subject has a predicted Irish model risk of DGF < 25%\n\n          -  Female subjects who are pregnant or breast feeding\n\n          -  Female subjects of child bearing potential who are unable or unwilling to use a\n             medically acceptable form of contraception\n\n          -  Subjects with a history of human immunodeficiency virus (HIV), or active hepatitis C\n             virus (HCV) or hepatitis B virus (HBV) infection\n\n          -  Subjects with active bacterial or other infection which is clinically significant in\n             the opinion of the Investigator\n\n          -  Subjects with a history of splenectomy\n\n          -  Subjects with  unresolved meningococcal disease\n\n          -  Subjects with an unresolved systemic bacterial or fungal infection\n\n          -  Subjects with known or suspected hereditary complement deficiency\n\n          -  Subject has a current malignancy or a history of any malignancy (within the past 5\n             years), except non-metastatic basal or squamous cell carcinoma of the skin or in situ\n             carcinoma of the cervix that has been treated appropriately\n\n          -  Subject has a history of or is believed by the Investigator to have used an illicit\n             drug(s) and/or abused alcohol within 3 months prior to screening\n\n          -  Subject has a psychiatric or physical illness that in the opinion of the Investigator\n             would interfere with the ability of the subject to participate in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "286", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02145182", 
            "org_study_id": "ECU-DGF-201", 
            "secondary_id": "2013-004650-25"
        }, 
        "intervention": [
            {
                "arm_group_label": "Active", 
                "description": "Eculizumab will be administered by intravenous (IV) infusion over 25-45 minutes for two doses (on day of transplant then 18-24 hours later).", 
                "intervention_name": "Eculizumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo will be administered by intravenous (IV) infusion over 25-45 minutes for two doses (on day of transplant then 18-24 hours later).", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "DGF", 
            "Dialysis", 
            "Kidney", 
            "Kidney Transplantation", 
            "eGFR", 
            "Complement", 
            "Eculizumab"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multi-center Study of Eculizumab for the Prevention of Delayed Graft Function After Kidney Transplantation in Adult Subjects at Increased Risk of Delayed Graft Function.", 
        "overall_contact": {
            "email": "clinicaltrials@alxn.com", 
            "last_name": "Alexion Pharmaceuticals (sponsor)"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "Czech Republic: State Institute for Drug Control", 
                "France: National Agency for the Safety of Medicine and Health Products (ANSM)", 
                "Italy: The Italian Medicines Agency", 
                "Germany: Paul-Ehrlich-Institut", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Brazil: National Health Surveillance Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective is to demonstrate efficacy and safety of a two dose regimen of eculizumab to prevent DGF in adult recipients of diseased donor kidney transplants who are at increased risk of DGF.", 
            "measure": "Incidence of DGF defined as the requirement for dialysis for any reason in the first seven days post-transplant", 
            "safety_issue": "No", 
            "time_frame": "First 7 days post Kidney Transplant"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02145182"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Graft function categorized into delayed graft function, functional delayed graft function, and immediate graft function", 
                "safety_issue": "No", 
                "time_frame": "During the first 7 days post-transplantation"
            }, 
            {
                "measure": "Dialysis post-transplantation", 
                "safety_issue": "No", 
                "time_frame": "During the first 30 days post-transplantation"
            }, 
            {
                "measure": "Calculated eGFR (Estimated Glomerular Filtration Rate)", 
                "safety_issue": "No", 
                "time_frame": "At day 28 post-transplantation"
            }, 
            {
                "description": "Rejection free graft survival defined as freedom from biopsy proven acute rejection, graft loss or subject death", 
                "measure": "Rejection free graft survival", 
                "safety_issue": "No", 
                "time_frame": "At 26 and 52 weeks post-transplantation"
            }
        ], 
        "source": "Alexion Pharmaceuticals", 
        "sponsors": {
            "collaborator": {
                "agency": "Clinical Trial and Consulting (CTI)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Alexion Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}